Natixis Advisors, L.P. Hutchmed (China) LTD Transaction History

Natixis Advisors, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.59 - $20.77 $93,536 - $226,164	-10,889 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$15.52 - $35.65 $91,645 - $210,513	-5,905 Reduced 35.16%	10,889 $206,000
Q4 2021 Feb 08, 2022	BUY	$28.89 - $35.33 $25,394 - $31,055	879 Added 5.52%	16,794 $589,000
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $27,386 - $32,977	768 Added 5.07%	15,915 $583,000
Q2 2021 Aug 12, 2021	SELL	$23.7 - $39.27 $22,278 - $36,913	-940 Reduced 5.84%	15,147 $595,000
Q1 2021 May 05, 2021	SELL	$27.01 - $36.8 $1,512 - $2,060	-56 Reduced 0.35%	16,087 $454,000
Q4 2020 Feb 12, 2021	SELL	$27.51 - $34.36 $1,513 - $1,889	-55 Reduced 0.34%	16,143 $517,000
Q3 2020 Nov 12, 2020	BUY	$25.8 - $34.61 $75,619 - $101,441	2,931 Added 22.09%	16,198 $523,000
Q2 2020 Aug 11, 2020	BUY	$17.65 - $28.05 $234,162 - $372,139	13,267 New	13,267 $366,000
Q1 2020 Apr 27, 2020	SELL	$15.19 - $29.51 $153,479 - $298,169	-10,104 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$17.17 - $25.95 $173,485 - $262,198	10,104 New	10,104 $253,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.73B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.